Brian O Mahony/ X
Jul 13, 2026, 19:47
Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
Brian O Mahony, CEO of Irish Haemophilia Society, shared a post on X:
“Feng Xue on BBM-H901 at ISTH 2026, FIX Gene therapy developed in China.
Approved in China April 2025.
Mean FIX expression after 2 years 61% Distribution :
- 76% FIX more than 40 ,
- 20% FIX less than 40,
- 10% FIX less than 20,
- 5% FIX less than 10,
- 2% FIX less than 2″
Other posts featuring Brian O Mahony on Hemostasis Today
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering